{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014253","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2024-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.074341+00:00","generated_at":"2026-06-04T00:18:56.995680+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Palisade Bio details PALI-2108 development for ulcerative colitis at IBD conference","bullets":["PALI-2108 is a colon-specific PDE4 inhibitor prodrug for moderate-to-severe ulcerative colitis.","Phase 1 clinical study planned to begin before year-end 2024.","Development supported by $500,000 research agreement with Giiant from the Crohn's & Colitis Foundation.","Presentation given at IBD Innovate in Cambridge, MA on April 9-10, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014253","json":"https://secwatch.observer/filing/0001493152-24-014253.json","markdown":"https://secwatch.observer/filing/0001493152-24-014253.md","text":"https://secwatch.observer/filing/0001493152-24-014253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315224014253/0001493152-24-014253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315224014253/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:18:56.995680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}